<DOC>
	<DOCNO>NCT02288312</DOCNO>
	<brief_summary>Single-centre , open-label , randomised , gender-balanced , 3-way crossover , 3-period , 3-sequence study 18 healthy male female subject .</brief_summary>
	<brief_title>Food Effect Dosage Form Proportionality Study Eslicarbazepine Acetate</brief_title>
	<detailed_description>Single-centre , open-label , randomised , gender-balanced , 3-way crossover , 3-period , 3-sequence study 18 healthy male female subject . The study consist 3 period separate washout 7 day dos . Subjects receive single oral 800 mg dose eslicarbazepine acetate follow standard meal one period , follow least 10 hour fast two period .</detailed_description>
	<mesh_term>Eslicarbazepine acetate</mesh_term>
	<criteria>Male female subject age 18 55 year , inclusive . Subjects body mass index ( BMI , kg/m2 ) within normal range [ 4 ] , i.e. , 18.50 24.99 , inclusive . Subjects healthy determine prestudy medical history , physical examination , vital sign , 12lead ECG . Subjects clinical laboratory test result clinically acceptable screen admission first treatment period . Subjects negative test HBsAg , antiHCVAb anti HIV1 HIV2 Ab screen . Subjects negative screen alcohol drug abuse screen . Subjects nonsmokers exsmokers discontinue smoke least 3 month prior admission . Subjects able willing give write informed consent . ( If female ) She childbearing potential reason surgery ( hysterectomy tubal ligation ) , childbearing potential , use one follow method contraception : intrauterine device ( study subject ) + condom ( partner ) , diaphragm ( study subject ) + condom ( partner ) , spermicide ( study subject ) + condom ( partner ) . ( If female ) She negative urine pregnancy test screen admission treatment period . Subjects conform inclusion criterion , Subjects clinically relevant history presence respiratory , gastrointestinal , renal , hepatic , haematological , lymphatic , neurological , cardiovascular , psychiatric , musculoskeletal , genitourinary , immunological , dermatological , endocrine , connective tissue diseases disorder . Subjects clinically relevant surgical history . Subjects clinically relevant family history . Subjects history relevant drug hypersensitivity . Subjects history alcoholism drug abuse . Subjects consume 14 unit alcohol week . Subjects use medicine within 2 week first admission , opinion investigator , may affect safety study assessment . Subjects use investigational drug participate clinical trial within 2 month first admission . Subjects previously receive eslicarbazepine acetate ( ESL , BIA 2093 ) . Subjects donate receive blood blood product within previous 2 month prior screen . Subjects vegetarian , vegan medical dietary restriction . Subjects could communicate reliably investigator . Subjects unlikely cooperate requirement study . Subjects unwilling unable give write informed consent . ( If female ) She pregnant breastfeeding . ( If female ) She childbearing potential use approve effective contraceptive method use oral contraceptive .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>